Hologic Inc. (HOLX)

The total asset value of Hologic Inc. (HOLX) stood at $ 10,404 Mln as on 31-Mar-23

The share price of Hologic Inc. (HOLX) is $70.210000 (NASDAQ) as of 22-Sep-2023 16:00 EDT. Hologic Inc. (HOLX) has given a return of 2.54% in the last 3 years.

Hologic Inc. (HOLX) has a market capitalisation of $ 19,493 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Hologic Inc. (HOLX) is 3.83 times as on 02-Jun-2023, a 0.36% premium to its peers’ median range of 2.82 times.

The P/E ratio of Hologic Inc. (HOLX) is 26.18 times as on 02-Jun-2023, a 0.2% premium to its peers’ median range of 21.83 times.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Hologic Inc. (HOLX) and enter the required number of quantities and click on buy to purchase the shares of Hologic Inc. (HOLX).

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima BV and Aptima CV/TV assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment, such as 2D and 3D digital mammography systems, image analytics software, reading workstations, ultrasound imaging, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and ultrasound and connectivity solutions, as well as breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology in the uterus; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; and the CoolSeal portfolio that includes bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. wa

The CEO & director of Mr. Stephen P. MacMillan. is Hologic Inc. (HOLX), and CFO & Sr. VP is Ms. Karleen M. Oberton.

The promoters of Hologic Inc. (HOLX) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

Yes, TTM profit after tax of Hologic Inc. (HOLX) was $753 Mln.